GWM
TGTX icon

Gibbs Wealth Management’s TG Therapeutics TGTX Stock Holding History

Gibbs Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$931K Buy
28,018
+12,032
+75% +$359K 0.12% 167
2025
Q4 		$455K Buy
+15,986
New +$522K 0.11% 212

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Gibbs Wealth Management's TGTX Position: Q1 2026 in Review

Gibbs Wealth Management increased its TG Therapeutics (TGTX) stake by 75% in Q1 2026, buying an estimated $359K and bringing the position to 28,018 shares worth $931K. The position accounts for 0.12% of the portfolio, ranked #167.

Gibbs Wealth Management first reported a position in TGTX in Q4 2025 and has held it in 2 quarters since. 365 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Gibbs Wealth Management held 28,018 shares of TG Therapeutics worth $931K as of Q1 2026.
  • Gibbs Wealth Management bought 12,032 TG Therapeutics shares in Q1 2026, an estimated $359K.
  • TG Therapeutics made up 0.12% of Gibbs Wealth Management's portfolio in Q1 2026, its #167 holding.
  • Gibbs Wealth Management first reported a position in TG Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 365 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Gibbs Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.